CARCINOMA STOMACH AETIOLOGY,CLASSIFICATION & CLINICAL FEATURES BY JOSE JAMES

Student at Stanley Medical College um Stanley Medical College
30. Nov 2018
CARCINOMA STOMACHAETIOLOGY,CLASSIFICATION & CLINICAL FEATURES BY JOSE JAMES
CARCINOMA STOMACHAETIOLOGY,CLASSIFICATION & CLINICAL FEATURES BY JOSE JAMES
CARCINOMA STOMACHAETIOLOGY,CLASSIFICATION & CLINICAL FEATURES BY JOSE JAMES
CARCINOMA STOMACHAETIOLOGY,CLASSIFICATION & CLINICAL FEATURES BY JOSE JAMES
CARCINOMA STOMACHAETIOLOGY,CLASSIFICATION & CLINICAL FEATURES BY JOSE JAMES
CARCINOMA STOMACHAETIOLOGY,CLASSIFICATION & CLINICAL FEATURES BY JOSE JAMES
CARCINOMA STOMACHAETIOLOGY,CLASSIFICATION & CLINICAL FEATURES BY JOSE JAMES
CARCINOMA STOMACHAETIOLOGY,CLASSIFICATION & CLINICAL FEATURES BY JOSE JAMES
CARCINOMA STOMACHAETIOLOGY,CLASSIFICATION & CLINICAL FEATURES BY JOSE JAMES
CARCINOMA STOMACHAETIOLOGY,CLASSIFICATION & CLINICAL FEATURES BY JOSE JAMES
CARCINOMA STOMACHAETIOLOGY,CLASSIFICATION & CLINICAL FEATURES BY JOSE JAMES
CARCINOMA STOMACHAETIOLOGY,CLASSIFICATION & CLINICAL FEATURES BY JOSE JAMES
CARCINOMA STOMACHAETIOLOGY,CLASSIFICATION & CLINICAL FEATURES BY JOSE JAMES
CARCINOMA STOMACHAETIOLOGY,CLASSIFICATION & CLINICAL FEATURES BY JOSE JAMES
CARCINOMA STOMACHAETIOLOGY,CLASSIFICATION & CLINICAL FEATURES BY JOSE JAMES
CARCINOMA STOMACHAETIOLOGY,CLASSIFICATION & CLINICAL FEATURES BY JOSE JAMES
CARCINOMA STOMACHAETIOLOGY,CLASSIFICATION & CLINICAL FEATURES BY JOSE JAMES
CARCINOMA STOMACHAETIOLOGY,CLASSIFICATION & CLINICAL FEATURES BY JOSE JAMES
CARCINOMA STOMACHAETIOLOGY,CLASSIFICATION & CLINICAL FEATURES BY JOSE JAMES
CARCINOMA STOMACHAETIOLOGY,CLASSIFICATION & CLINICAL FEATURES BY JOSE JAMES
CARCINOMA STOMACHAETIOLOGY,CLASSIFICATION & CLINICAL FEATURES BY JOSE JAMES
CARCINOMA STOMACHAETIOLOGY,CLASSIFICATION & CLINICAL FEATURES BY JOSE JAMES
CARCINOMA STOMACHAETIOLOGY,CLASSIFICATION & CLINICAL FEATURES BY JOSE JAMES
CARCINOMA STOMACHAETIOLOGY,CLASSIFICATION & CLINICAL FEATURES BY JOSE JAMES
CARCINOMA STOMACHAETIOLOGY,CLASSIFICATION & CLINICAL FEATURES BY JOSE JAMES
CARCINOMA STOMACHAETIOLOGY,CLASSIFICATION & CLINICAL FEATURES BY JOSE JAMES
CARCINOMA STOMACHAETIOLOGY,CLASSIFICATION & CLINICAL FEATURES BY JOSE JAMES
CARCINOMA STOMACHAETIOLOGY,CLASSIFICATION & CLINICAL FEATURES BY JOSE JAMES
CARCINOMA STOMACHAETIOLOGY,CLASSIFICATION & CLINICAL FEATURES BY JOSE JAMES
CARCINOMA STOMACHAETIOLOGY,CLASSIFICATION & CLINICAL FEATURES BY JOSE JAMES
CARCINOMA STOMACHAETIOLOGY,CLASSIFICATION & CLINICAL FEATURES BY JOSE JAMES
CARCINOMA STOMACHAETIOLOGY,CLASSIFICATION & CLINICAL FEATURES BY JOSE JAMES
CARCINOMA STOMACHAETIOLOGY,CLASSIFICATION & CLINICAL FEATURES BY JOSE JAMES
CARCINOMA STOMACHAETIOLOGY,CLASSIFICATION & CLINICAL FEATURES BY JOSE JAMES
CARCINOMA STOMACHAETIOLOGY,CLASSIFICATION & CLINICAL FEATURES BY JOSE JAMES
CARCINOMA STOMACHAETIOLOGY,CLASSIFICATION & CLINICAL FEATURES BY JOSE JAMES
CARCINOMA STOMACHAETIOLOGY,CLASSIFICATION & CLINICAL FEATURES BY JOSE JAMES
CARCINOMA STOMACHAETIOLOGY,CLASSIFICATION & CLINICAL FEATURES BY JOSE JAMES
CARCINOMA STOMACHAETIOLOGY,CLASSIFICATION & CLINICAL FEATURES BY JOSE JAMES
CARCINOMA STOMACHAETIOLOGY,CLASSIFICATION & CLINICAL FEATURES BY JOSE JAMES
CARCINOMA STOMACHAETIOLOGY,CLASSIFICATION & CLINICAL FEATURES BY JOSE JAMES
CARCINOMA STOMACHAETIOLOGY,CLASSIFICATION & CLINICAL FEATURES BY JOSE JAMES
CARCINOMA STOMACHAETIOLOGY,CLASSIFICATION & CLINICAL FEATURES BY JOSE JAMES
CARCINOMA STOMACHAETIOLOGY,CLASSIFICATION & CLINICAL FEATURES BY JOSE JAMES
CARCINOMA STOMACHAETIOLOGY,CLASSIFICATION & CLINICAL FEATURES BY JOSE JAMES
CARCINOMA STOMACHAETIOLOGY,CLASSIFICATION & CLINICAL FEATURES BY JOSE JAMES
CARCINOMA STOMACHAETIOLOGY,CLASSIFICATION & CLINICAL FEATURES BY JOSE JAMES
CARCINOMA STOMACHAETIOLOGY,CLASSIFICATION & CLINICAL FEATURES BY JOSE JAMES
CARCINOMA STOMACHAETIOLOGY,CLASSIFICATION & CLINICAL FEATURES BY JOSE JAMES
CARCINOMA STOMACHAETIOLOGY,CLASSIFICATION & CLINICAL FEATURES BY JOSE JAMES
CARCINOMA STOMACHAETIOLOGY,CLASSIFICATION & CLINICAL FEATURES BY JOSE JAMES
CARCINOMA STOMACHAETIOLOGY,CLASSIFICATION & CLINICAL FEATURES BY JOSE JAMES
CARCINOMA STOMACHAETIOLOGY,CLASSIFICATION & CLINICAL FEATURES BY JOSE JAMES
CARCINOMA STOMACHAETIOLOGY,CLASSIFICATION & CLINICAL FEATURES BY JOSE JAMES
CARCINOMA STOMACHAETIOLOGY,CLASSIFICATION & CLINICAL FEATURES BY JOSE JAMES
CARCINOMA STOMACHAETIOLOGY,CLASSIFICATION & CLINICAL FEATURES BY JOSE JAMES
CARCINOMA STOMACHAETIOLOGY,CLASSIFICATION & CLINICAL FEATURES BY JOSE JAMES
CARCINOMA STOMACHAETIOLOGY,CLASSIFICATION & CLINICAL FEATURES BY JOSE JAMES
CARCINOMA STOMACHAETIOLOGY,CLASSIFICATION & CLINICAL FEATURES BY JOSE JAMES
CARCINOMA STOMACHAETIOLOGY,CLASSIFICATION & CLINICAL FEATURES BY JOSE JAMES
CARCINOMA STOMACHAETIOLOGY,CLASSIFICATION & CLINICAL FEATURES BY JOSE JAMES
CARCINOMA STOMACHAETIOLOGY,CLASSIFICATION & CLINICAL FEATURES BY JOSE JAMES
CARCINOMA STOMACHAETIOLOGY,CLASSIFICATION & CLINICAL FEATURES BY JOSE JAMES
1 von 63

Más contenido relacionado

Was ist angesagt?

Gastric cancer presentation finalGastric cancer presentation final
Gastric cancer presentation finalTamer Madi
Gastric Cancer ( stomach tumor )Gastric Cancer ( stomach tumor )
Gastric Cancer ( stomach tumor )D.A.B.M
Carcinoma stomach   managementCarcinoma stomach   management
Carcinoma stomach managementShriyans Jain
Gasric cancerGasric cancer
Gasric cancerLala Gladson Ananda Robin
Gastric cancerGastric cancer
Gastric cancerDr KAMBLE
 carcinoma of  stomach carcinoma of  stomach
carcinoma of stomachVeeru Reddy

Similar a CARCINOMA STOMACH AETIOLOGY,CLASSIFICATION & CLINICAL FEATURES BY JOSE JAMES

Gastric CarcinomaGastric Carcinoma
Gastric CarcinomaSaeed Al-Shomimi
Carcinoma stomachCarcinoma stomach
Carcinoma stomachLEOFREDERICK
Stomach CancerStomach Cancer
Stomach CancerDr Neelesh Bhandari
Carcinoma stomach- A Brief Overview- Part 1Carcinoma stomach- A Brief Overview- Part 1
Carcinoma stomach- A Brief Overview- Part 1Suman Baral
CARCINOMA STOMACHCARCINOMA STOMACH
CARCINOMA STOMACHAbhishek Thakur
Inflammatory Bowel DiseaseInflammatory Bowel Disease
Inflammatory Bowel DiseaseOrangzeb Khatri

Último

Chương 3. Tài liệu EU GMP.pdfChương 3. Tài liệu EU GMP.pdf
Chương 3. Tài liệu EU GMP.pdfCông ty cổ phần GMPc Việt Nam | Tư vấn GMP, HS GMP, CGMP ASEAN, EU GMP, WHO GMP
5 reasons to choose weed delivery miami5 reasons to choose weed delivery miami
5 reasons to choose weed delivery miamiBlayzeweed
Chương 6. Tài liệu EU GMP.pdfChương 6. Tài liệu EU GMP.pdf
Chương 6. Tài liệu EU GMP.pdfCông ty cổ phần GMPc Việt Nam | Tư vấn GMP, HS GMP, CGMP ASEAN, EU GMP, WHO GMP
Expert Insights on Optimizing Patient Outcomes With Novel EHL FVIII Strategie...Expert Insights on Optimizing Patient Outcomes With Novel EHL FVIII Strategie...
Expert Insights on Optimizing Patient Outcomes With Novel EHL FVIII Strategie...PVI, PeerView Institute for Medical Education
ADA 2023..pdfADA 2023..pdf
ADA 2023..pdfHistologafcilENFOMEC
Early Childhood Focus Group PresentationEarly Childhood Focus Group Presentation
Early Childhood Focus Group PresentationChesapeakeVirginiaWe

Último(20)

CARCINOMA STOMACH AETIOLOGY,CLASSIFICATION & CLINICAL FEATURES BY JOSE JAMES

Hinweis der Redaktion

  1. Malignant tumors-93% Carcinoma-88% Lymphoma-3% Leiomyosarcoma 1.7%
  2. Diet and environmental
  3. Cadherins (named for "calcium-dependent adhesion") are a type of cell adhesion molecule (CAM) that is important in the formation of adherens junctions to bind cells with each other. Familial—10%. Napoleon. Familial gastric cancer in associated with mutation of e-cadherin gene (90% risk).hereditary diffuse gastric cancer. prophylactic total gastrectomy should be considered for patients with this mutation Impairment/lack of adhesion molecule E-cadherin ▪ Genetic mutation (germline, somatic, epigenetic methylation) of CDH1 gene → inactivation of CDH1 → non-functional E-cadherin → unregulated division (impaired tumour suppressor function); increased ability to spread, invade adjacent structures Loss of E-cadherin function or expression has been implicated in cancer progression and metastasis.[10][11] E-cadherin downregulation decreases the strength of cellular adhesion within a tissue, resulting in an increase in cellular motility. This in turn may allow cancer cells to cross the basement membrane and invade surrounding tissues APC GENE Adenomatous polyposis coli (APC) also known as deleted in polyposis 2.5 (DP2.5) is a protein that in humans is encoded by the APC gene.[4] The APC protein is a negative regulator that controls beta-catenin concentrations and interacts with E-cadherin, which are involved in cell adhesion. Mutations in the APC gene may result in colorectal cancer. Hereditary Non Polyposis Colorectal Cancer Autosomal dominant disorder Defect in mismatch gene repair These errors activate proto oncogenes and inactivate tumour suppressor genes Microsatellite instability also causes similar defects Li-Fraumeni syndrome Associated with germline mutation in TP53 gene Sarcomas, leukemia, brain tumors, breast and adrenal cortical carcinomas are commonly associated Gastric mucosa of people with blood group ‘A’ is more susceptible for carcinogens—diffuse type. It is due to different mucopolysaccharide secretion in stomach of blood group A patients who are more susceptible for carcinogens
  4. Schwartz's Principles of Surgery 10e -fragile histidine triad protein (FHIT) is an encoded by the FHIT gene.(DCC-methylation in deleted in colorectal carcinoma The most common genetic abnormalities in sporadic gastric cancer affect the p53 and COX-2 genes. Over two thirds of gastric cancers have deletion or suppression of the important tumor-suppressor gene p53. Additionally, approximately the same proportion have overexpression of COX-2. In the colon, tumors with upregulation of this gene have suppressed apoptosis, more angiogenesis, and higher metastatic potential. Gastric tumors that overexpress COX-2 are more aggressive tumors. Recently, a germline mutation in the CDH1 gene encoding E-cadherin was shown to be associated with hereditary diffuse gastric cancer. Prophylactic total gastrectomy should be considered in patients with these mutations. The c-met proto-oncogene is the receptor for the hepatocyte growth factor and is frequently overexpressed in gastric cancer, as are the k-sam and c-erbB2 oncogenes. Inactivation of the tumor suppressor genes p53 and p16 has been reported in diffuse and intestinal-type cancers, whereas adenomatous polyposis coli gene mutations tend to be more frequent in intestinal-type gastric cancers.
  5. Ingested nitrates and nitrites from preserved food are converted to nitrosamines by GI bacteria ,Fruits and vegetables rich in vitamin ‘C’ protect from carcinoma stomach The mechanism is thought to be the conversion of nitrates in the food to N-nitroso compounds by bacteria in the stomach. N-nitroso compounds are also found in tobacco smoke, another known risk factor for gastric cancer. There is likely synergism between diet and H. pylori infection, with the bacteria increasing carcinogen production and inhibiting its removal. H. pylori has been shown to promote the growth of the bacteria that generate the carcinogenic N-nitroso compounds. At the same time, H. pylori can inhibit the secretion of ascorbic acid, preventing effective scavenging of oxygen free radicals and N-nitroso compounds.
  6. Proinflammatory cytokines and adipokines are produced by intra-abdominal visceral fat In western countries, carcinoma stomach is more common in proximal, near OG junction. Obesity, young individual, white people, smoking, alcohol intake, gastro-oesophageal reflux, higher social status, high calorie diet and probably genetic factors are the causes for proximal gastric cancers. It is more aggressive, spreads early due to thin muscularis mucosa. It is often diagnosed late. Signet ring type is common. It carries poor prognosis. It needs esophageal resection.
  7. cytoxan-associated gene A (cagA) Spiral-shaped or curved bacilli, Present in almost all patients with stomach ulcers, Spreads by faeco-oral route Virulence due to Flagella , Urease, Adhesins, Toxins Host factors – increased pro-inflammatory; decreased anti-inflammatory The primary mechanism is presence of chronic inflammation. Long-term infection with the bacteria leads to gastritis, primarily within the gastric body, with ventral gastric atrophy. These include overexpression of cyclooxygenase-2 and cyclin D2, p53 mutations, microsatellite instability, decreased p27 expression, and alterations in transcription factors such as CDX1 and CDX2
  8. Agammaglobulinaemia X linked disease Absence of mature B cells => lack of immunoglobulins No defense against infections Prone to H.pylori infection Epstein-Barr virus infection Associated with 10% of carcinoma stomach After primary infection establishes a latent infection Causes recombinant epithelial cell DNA Pernicious anemia High risk 6 times Associated with autoimmune atrophic gastritis
  9. Sabiston Textbook of Surgery
  10. Chronic atrophic gastritis (Fig. 26-53) is by far the most common precursor for gastric cancer, particularly the intestinal subtype (see Fig. 26-52). The prevalence of atrophic gastritis is higher in older age groups, but it is also common in younger people in areas with a high incidence of gastric cancer. In many patients, it is likely that H. pylori is involved in the pathogenesis of atrophic gastritis.
  11. CD4+T cells Diffuse gastric atrophy Hypergastrinaemia Endocrine cell hyperplasia => metaplasia A for autoimmune-abs(parietal cells)-Atrophic gastritis-Achlorhydria-anemia(pernicious) Affects-Body and Fundus
  12. Associated with H.pylori Patchy mucosal atrophy Normal gastrin levels Intestinal Metaplasia => Adenocarcinoma Antral predominant-Antral ca Pan gastritis-anywhere.
  13. Schwartz's Principles of Surgery 10e
  14. Intestinal metaplasia: Risk of carcinoma depends on extent of metaplasia in mucosa. H. pylori eradication is important here. Based on histological and biochemical nature, two types are found: Complete: Glands are completely lined with goblet cells and intestinal absorptive cells indistinguishable histologically and biochemically from their small bowel counterparts. Incomplete: It contains columnar cells, goblet cells but without intestinal absorptive cells. It also can be: Type I—Mature; goblet cells secret sialomucin. Type II—Cells in different levels of dedifferentiation. Cells secrete sialomucin and an abnormal sialomucin (sulphomucin)—a small quantity. Type III—Marked dedifferentiation of cells, secreting mainly sulphomucin.
  15. Causes: H.pylori, NSAIDS, smoking Currently associated more with NSAIDS than H.pylori Chronic benign gastric ulcer Chronic benign gastric ulcer Carcinoma arising from benign gastric ulcer is called as ulcer cancer of stomach
  16. Carcinoma arising from benign gastric ulcer is called as ulcer cancer of stomach
  17. Ménétrier’s disease is generally considered to carry a 5% to 10% risk of adenocarcinoma.
  18. Chronic benign gastric ulcer Carcinoma arising from benign gastric ulcer is called as ulcer cancer of stomach
  19. High grade or low grade Grading – epithelial enlargement, elongation, crowding, and hyperchromasia of nuclei. (FAP) have a high prevalence of gastric adenomatous polyps (about 50%), 10 times more likely to develop adenocarcinoma of the stomach than the general population Gastric polyps greater than 1cm should be removed to confirm the diagnosis and to eliminate any risk of malignant degeneration.
  20. (FAP) have a high prevalence of gastric adenomatous polyps (about 50%), 10 times more likely to develop adenocarcinoma of the stomach than the general population Gastric polyps greater than 1cm should be removed to confirm the diagnosis and to eliminate any risk of malignant degeneration.
  21. After Billroth 2 GJ/ Vagotomy + GJ STUMP CA
  22. Correa described three distinct patterns of chronic atrophic gastritis: autoimmune (involves the acid-secreting proximal stomach), hypersecretory (involving the distal stomach), and environmental (involving multiple random areas at the junction of the oxyntic and antral mucosa)
  23. Schwartz's Principles of Surgery 10e
  24. SIEWERT CLASSIFICATION Proximal gastric adenocarcinoma Type1:carcinoma in Barrett's oesophagus extending to GE junction Type2: Tumour within 2cm of squamocolumnar junction Type 3 : Tumour in sub cardial region MORPHOVOLUMETRIC CLASSIFICATION -Based on ratio of invasion into muscle to mucosa in advanced carcinoma Funnel type: mucosa involvement is more compared to muscle with ratio <0.15 columnar type: equal involvement of ratio 0.75-1.25 Mountain type: muscle invasion is more with ratio <1.25 MING CLASSIFICATION Expanding -better prognosis Infiltrate -poor prognosis MORSON AND DAWSON CLASSIFICATION Nodular ulcerated fungating Linitis plastica
  25. 1.Papillary-Most common- Frequently associated with liver metastasis and high rate of lymph node involvement- Histology epithelial projections scaffolded by central fibrovascular core 2.Tubular adenocarcinoma characterized by irregular shaped and fused neoplastic glands with intraluminal mucus and debris 3.Mucinous-clusters and scattered tumour cells floating in abundant extra cellular mucin Signet ring adenocarcinoma signet cells characterized by large cytoplasmic mucin vacuoles and peripherally displaced crescent shaped nuclei
  26. Types A-Intestinal(53%)-good prognosis B-Diffuse(33%)-poor prognosis C-Others-Unclassified(14%)
  27. CLASSIFICATION BASED ON DEPTH OF INVASION Early gastric cancer-only mucosa and sub mucosa involved Advanced gastric cancer-involvement of muscularis or serosa Early Gastric CA 10% have nodal metastasis nodal spread depends on tumour size[>2cm]. 70% are well differentiated Cure rate with adequate gastric resection and lymphadenectomy is 95%
  28. POLYPOID Tumour grows outwards from the stomach wall No area of erosion or ulceration seen ULCERATED WITH CLEAR CUT MARGIN Ulcers with well defined and sharp margins not infiltrative ULCERATED WITHOUT CLEAR CUT MARGIN ulcers with irregular,hard,stiff margins deep with raised and everted edge loss of rugosity seen areas of dead tissues [necrosis] within ulcer Infiltrative Diffuse carcinoma - Linitis plastica-Involving sub mucosa and deeper layers poorly differentiated type lacking glandular formation thickening of gastric wall and loss of rugal folds type IV gastric cancer and has poor prognosis spread: transmural, intraperitoneal and lymphatic
  29. Diffuse carcinoma - Linitis plastica-Involving sub mucosa and deeper layers poorly differentiated type lacking glandular formation thickening of gastric wall and loss of rugal folds type IV gastric cancer and has poor prognosis spread: transmural, intraperitoneal and lymphatic
  30. Acanthosis nigricans is a skin condition characterized by areas of dark, velvety discoloration in body folds and creases. The affected skin can become thickened. Most often, acanthosis nigricans affects your armpits, groin and neck. An Irish node is an enlarged axillary lymph node, often associated with advanced gastric cancer
  31. Asymptomatic initially ▪ Early symptoms ▫ Vague constitutional symptoms (e.g. malaise, loss of appetite, dyspepsia)
  32. ▪ With disease progression ▫ Epigastric pain, nausea, vomiting dysphagia, weight loss
  33. succussion splash- positive(checked with 4-6 hrs. empty stomach).
  34. ▪ If GI bleeding ▫ Anaemia, melena, coffee-ground hematemesis ▪ Pseudo achalasia syndrome (difficulty moving food, liquids from oesophagus to stomach) ▫ If tumour extends to Auerbach’s plexus/obstruction occurs near gastroesophageal junction
  35. The Trousseau sign of malignancy or Trousseau's syndrome is a medical sign involving episodes of vessel inflammation due to blood clot (thrombophlebitis) which are recurrent or appearing in different locations over time (thrombophlebitis migrans or migratory thrombophlebitis). The location of the clot is tender and the clot can be felt as a nodule under the skin.[1] Trousseau's syndrome is a rare variant of venous thromboembolism (VTE) that is characterized by recurrent, migratory thrombosis in superficial veins and in uncommon sites, such as the chest wall and arms. This syndrome is particularly associated with pancreatic, gastric and lung cancer and Trousseau's syndrome can be an early sign of cancer[2][3] sometimes appearing months to years before the tumor would be otherwise detected.[4] Heparin therapy is recommended to prevent future clots.
  36. DIRECT SPREAD Horizontal submucosal spread along stomach wall Vertical spread by invasion to adjacent structures The stomach cancer tumour spreads by direct invasion into surrounding tissues and blood vessels.
  37. LYMPHATIC SPREAD LYMPH NODE GROUPS Perigastric nodes Along the root of major vessels Along the root of superior mesenteric artery and hepatoduodenal ligament Distant lymph nodes
  38. Involvement of left supra clavicular node[virchow’s node] Sign of advanced stage of metastasis of the tumor
  39. cannonball lung Mets
  40. Peritoneal seedlings-Ascites Liver Mets
  41. Krukenberg’s tumour involving ovaries
  42. Krukenberg’s tumour involving ovaries